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BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1)
expression measured by immunohistochemistry may predict response to anti–programmed cell death 1 (PD-1)
therapy. Results on the association between PD-L1 expression and survival among patients with advanced non–
small cell lung cancer (NSCLC) treated with chemotherapy are inconsistent. MATERIAL AND METHODS: We
evaluated the relationship between PD-L1 expression and overall survival (OS) among 204 patients with advanced
NSCLC treated at Aarhus University Hospital, Aarhus, Denmark, from 2007 to 2012. PD-L1 expression was
measured using a prototype immunohistochemistry assay with the anti–PD-L1 22C3 antibody (Merck). PD-L1
strong positivity and weak positivity were defined to be traceable to the clinical trial version of the assay. RESULTS:
Twenty-five percent of patients had PD-L1 strong-positive tumors, and 50% had PD-L1 weak-positive tumors. No
statistically significant association was found between PD-L1 expression and survival; adjusted hazard ratio of 1.34
(95% confidence interval, 0.88-2.03; median OS, 9.0 months) for the PD-L1 strong-positive group and 1.07 (0.74-
1.55; median OS, 9.8 months) for the PD-L1 weak-positive group compared with the PD-L1–negative group
(median OS, 7.5 months). No association was seen between PD-L1 expression and OS when PD-L1
expression levels were stratified by median or tertiles. CONCLUSIONS: In concordance with previous studies,
we found PD-L1 measured by immunohistochemistry to be frequently expressed in patients with advanced
NSCLC. However, PD-L1 expression is not a strong prognostic marker in patients with advanced NSCLC
treated with chemotherapy.
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Non–small cell lung cancer (NSCLC) has a poor prognosis and is a
leading cause of cancer death worldwide [1]. The majority of patients
are diagnosed when their disease has reached an advanced stage,
which leaves palliative treatment as the only option for therapy.
Recent years have seen improvements in treatment options,
particularly for subgroups of patients harboring specific drug-treatable
genetic tumor alterations such as mutations in the epidermal growth
factor receptor or the EML4-ALK translocation [2]. Therapy with
monoclonal antibodies directed against programmed cell death 1
(PD-1) or its corresponding ligand, programmed cell death ligand 1
(PD-L1), has yielded impressive results in recent clinical trials and is a
promising new treatment option for patients with advanced NSCLC
[3–5]. PD-L1 expression measured by immunohistochemistry
appears to be a predictive marker for most patients receiving this
therapy [6]. Platinum-based doublet chemotherapy remains the
cornerstone of palliative systemic treatment of NSCLC, but 50% to
60% of patients experience progressive disease while on this therapy
[7,8]. Investigations have explored the use of various biomarkers for
response to chemotherapy, such as excision repair cross-complementation
group 1, β-tubulin class III, expression of epidermal growth factor
receptor, and genetic expression profiles. None of these have, as yet,
reached clinical usage [9]. Continuous investigation in biomarkers to
optimize patient selection is therefore needed.
The PD-1/PD-L1 interaction is one of the major pathways used by
some tumors to escape immune surveillance. PD-1 is an immuno-
globulin superfamily member that has been shown to negatively
regulate antigen receptor signaling upon engagement of its ligands
(PD-L1 and/or PD-L2) [10–12]. Studies using various PD-L1
detection antibodies and immunohistochemistry assays have found
that a high level of PD-L1 expression in tumor cells correlates with
poor prognosis in several human cancers, including breast, lung,
renal, and melanoma [13–21]. Other studies have suggested a positive
or no correlation between PD-L1 expression and survival among
patients with cancer [22,23]. Three recently published meta-analyses
evaluated the prognostic significance of PD-L1 expression on tumor
cells. Zhang et al. analyzed the results from 29 studies concerning
PD-L1 expression in cancer originating from epithelium, including 6
studies in patients with NSCLC [24]. The authors concluded that
positive PD-L1 expression (compared with PD-L1–negative expres-
sion) measured by immunohistochemistry was associated with shorter
overall survival (OS) (hazard ratio [HR], 1.81; 95% confidence
interval [CI], 1.33-2.46). However, a subgroup analysis discovered no
association in six studies of patients with NSCLC (HR, 1.35; 95%
CI, 0.81-2.23) [24]. Reviewing data from 1157 and 877 patients with
NSCLC, in cancer stages I to IV from 6 and 5 published studies,
respectively, the 2 other meta-analyses concluded that high PD-L1
expression is associated with worse survival (HR, 1.75; 95% CI,
1.40-2.20 and HR, 1.43; 95% CI, 1.24-1.63) [25,26]. A recent study
found PD-L1–positive expression, particularly PD-L1 strong-positive
expression, to be associated with worse survival among Korean
patients with early-stage NSCLC treated with surgery [27]. However,
the negative prognostic value was not statistically significant after
adjusting for postsurgical chemotherapy or radiotherapy. Currently,
data are limited on whether PD-L1 expression is associated with
survival among patients with advanced NSCLC treated with palliative
chemotherapy.
The aim of the present study was to characterize PD-L1 expression
levels measured by immunohistochemistry among patients withadvanced NSCLC. A secondary aim was to investigate the association
between PD-L1 expression and OS in patients with NSCLC receiving
standard chemotherapy as their initial treatment.
Materials and Methods
Patients
Patients with advanced NSCLC who were treated at the
Department of Oncology, Aarhus University Hospital, in Aarhus,
Denmark, from 2007 to 2012 were eligible. The inclusion criteria
were as follows: stage IIIa, IIIb, or IV NSCLC; first-line palliative
treatment with platinum-based doublet chemotherapy; World Health
Organization (WHO) performance status 0 to 2; and sufficient tumor
tissue available for immunohistochemical analysis. Concomitant
palliative radiotherapy was allowed. Clinicopathologic data were
obtained by review of medical records. A computed tomographic scan
of the thorax and upper abdomen with intravenous (IV) contrast was
performed every 2 to 3 months during treatment and follow-up. This
retrospective study was conducted in concordance with relevant local
and regional guidelines and was approved by the regional ethics
committee (reference number: 1-10-72-578-12) and the regional data
protecting authority (reference number: 1-16-02-29-13).
PD-L1 Immunohistochemistry
PD-L1 expression was measured on the formalin-fixed, paraffi-
n-embedded tumor samples acquired from diagnostic tumor biopsies.
A prototype immunohistochemistry assay with the anti–PD-L1 22C3
antibody (Merck & Co., Inc., Kenilworth, NJ) was used. This assay
uses the same primary antibody and ancillary reagents as the assay
used in clinical trials of pembrolizumab [3] but uses a staining
instrument that is no longer commercially available, uses an overnight
incubation of the primary antibody, and includes both a low pH and
proteinase K antigen retrieval. A brief overview of the prototype assay
methodology is as follows: 4- to 5-μm sections of each sample were
cut onto positively charged slides. Slides were then baked,
deparaffinized in xylene, and rehydrated via an ethanol series. A
low-pH target-retrieval solution (#S1700, Dako, Carpinteria, CA)
was used for antigen retrieval, along with a 10-minute proteinase K
incubation (#S3020, Dako) following a 1× wash buffer rinse
(#K8012 Envision FLEX+ kit, Dako) as part of automated staining.
Automated staining (QualTek TekMate 500, Newtown, PA) was
followed by peroxidase blocking (#K8012, Dako). Slides were
incubated overnight with the 22C3 antibody with a primary antibody
diluent (#S0908 Primary Antibody Diluent, Dako). Secondary
detection and chromogen deposition (#K8012-EnVision FLEX+
Mouse, horseradish peroxidase–polymer reagent, and diaminobenzi-
dine chromogen; Dako) were performed with 1× wash buffer rinse
between each incubation. Slides were counterstained with hematox-
ylin, washed in 1× wash buffer, rinsed in distilled water, rehydrated
through an ethanol series, and rinsed in xylene changes. Slides were
then mounted with Cytoseal mounting media (#8312, Thermo
Scientific, Waltham, MA) and coverslipped. Each staining run
contained positive and negative controls along with a negative
isotype-matched antibody control for each sample.
A board-certified pathologist evaluated all stained slides for PD-L1
membrane staining. Using the clinical trial assay to identify levels of
PD-L1 expression that maximally predict clinical response to
pembrolizumab, PD-L1 weak positive is defined as membranous
PD-L1 expression in 1% to 49% of tumor cells, and PD-L1 strong
Table 1. Baseline Characteristics and Prevalence of Strong-Positive, Weak-Positive, and Negative
PD-L1 Expression
Subgroup N PD-L1 Expression P
Value
Strong Positive Weak Positive Negative
n (%) n (%) n (%)
Overall 204 51 (25.0) 102 (50.0) 51 (25.0)
Sex
Women 112 25 (22.3) 57 (50.9) 30 (26.8) .58
Men 92 26 (28.3) 45 (48.9) 21 (22.8)
Age
b65 years 96 23 (24.0) 46 (47.9) 27 (28.1) .65
≥65 years 108 28 (25.9) 56 (51.9) 24 (22.2)
Smoking status
Current 139 33 (23.7) 74 (53.2) 32 (23.0) .49
Former or never 65 18 (26.7) 28 (43.1) 19 (29.2)
Histology
Squamous 44 9 (20.5) 26 (59.1) 9 (20.5) .40
Nonsquamous 160 42 (26.3) 76 (47.5) 42 (26.3)
WHO performance status
0 92 23 (25.0) 52 (56.5) 17 (18.5) .08
1/2 106 25 (23.6) 47 (44.3) 34 (32.1)
Unknown 6 3 (50.0) 3 (50.0) 0 (0.0)
Fisher exact test.
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data from 242 independent NSCLC tumors that were tested with
both the prototype and clinical trial assays, the corresponding cutoffs
using the prototype assay are 1% to 95% for weak positive and ≥96%
for strong positive. Using these cutoffs, the “positive versus negative”
and “strong positive versus not strong positive” concordances were
maximized between the assays (89% concordance). Of note, the
higher cutoffs identified for the prototype assay are likely the result of
the darker stain produced with the prototype assay, which is likely due
to the longer antibody incubation or the double antigen retrieval.
Figure 1 shows examples of PD-L1 staining using the prototype assay.
Statistical Analysis
The prevalence of PD-L1 strong and weak positivity was compared
in subgroups based on age, sex, smoking status, histology, and cancer
stages using the χ2 test. OS was defined as the time from the date of
first chemotherapy cycle to the date of death or last follow-up.
Kaplan-Meier methods, the log-rank test, and Cox proportional
hazard models were used for survival analysis. For these analyses, the
PD-L1–negative group was used as the reference group, and
adjustment was made for age, sex, histology, smoking, and
performance status. We also explored the association between
PD-L1 expression and survival when PD-L1 expression levels were
stratified by median or tertiles, or used as continuous variables.
Results
Patient Characteristics
The medical records of 449 patients with advanced NSCLC were
reviewed, and 204 patients fulfilled the eligibility criteria. Clinico-
pathologic baseline characteristics are presented in Table 1. The
median age at diagnosis was 65 years (range, 33-86 years), and 112
(55%) patients were women. Adenocarcinoma was the most frequent
histologic subtype (72%). A total of 139 (68%) patients were current
smokers, 63 (31%) patients were former or never smokers, and 2
(1%) patients had no information on smoking status. Most patients
(88%) were diagnosed with stage IV NSCLC. The WHO
performance status was 0 in 92 (45%) patients and 1 or 2 in 106
(52%) patients. Six (3%) patients had missing information on
performance status at baseline. All patients received platinum-doublet
chemotherapy as initial therapy, and 83% were treated with up to 4
cycles of carboplatin (area under the time-concentration curve 5, IV)/
vinorelbine (60-80 mg/m2, oral). Four cycles of carboplatin/
vinorelbine/bevacizumab (7.5 mg/kg, IV), followed by bevacizumab
maintenance (if response or disease stabilization was obtained) until
progression was administered to 15% of the patients. Two percent ofFigure 1. Examples of PD-L1 immunohistocehmistry staining in NSCL
the chromogranin (brown); the counterstain is hematoxylin (blue). PD-
the clinical trial version of the assay, which is currently used in the ppatients were treated with other platinum-doublet regimens.
Palliative radiotherapy given concomitantly with initial chemotherapy
was administered to 32% of the patients. Median follow-up duration
was 10.6 months (95% CI, 8.5-11.7).
PD-L1 Expression
Representative examples of PD-L1–negative, weak-positive, and
strong-positive immunohistochemical staining are shown in Figure 1.
PD-L1 strong-positive staining and weak-positive staining were
observed in 25% and 50% of patients, respectively. The remaining
25% of patients showed staining in b1% of cells and were considered
PD-L1 negative. There was no statistically significant association
between PD-L1 expression and age, sex, histology, or smoking status
in these patients with predominantly stage IV NSCLC (Table 1).
Survival Analysis
No statistically significant association was observed between
PD-L1 expression and survival (log-rank test, P = 0.33; Figure 2).
The crude HR was 1.31 (95% CI, 0.88-1.97; median OS, 9.0
months) for the PD-L1 strong-positive group and 1.04 (95% CI,
0.73-1.49; median OS, 9.8 months) for the PD-L1 weak-positive
group when compared with the PD-L1–negative group (median OS,
7.5 months) (Table 2). The adjusted HR was 1.36 (95% CI,
0.90-2.06) for the PD-L1 strong-positive group and 1.09 (95% CI,C tumor specimens. PD-L1 staining is evident from the presence of
L1 strong positivity and weak positivity were defined as traceable to
embrolizumab clinical trials.
Figure 2. Kaplan-Meier curves of overall survival since the start of chemotherapy, stratified by PD-L1 expression.n=204; log-rank test,P=0.33.
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PD-L1–negative group. No association was observed between PD-L1
expression and OS when PD-L1 expression levels were stratified by
the median or tertiles, or when the PD-L1 immunohistochemistry
score was treated as a continuous variable. Similar results were
observed when calculating OS from time when patients received the
second line of systemic treatment (log-rank test, P = 0.38). In the
subgroup analysis by histology, we observed a stronger association
between PD-L1 expression and OS among patients with squamous
cell histology than among patients with adenocarcinoma. However,
the sample size in this subgroup was small (Table 2).
Discussion
Immunotherapy for lung cancer is evolving quickly and has the
potential to revolutionize cancer treatment. Previous clinical trials
have shown impressive overall response rates in heavily pretreatedTable 2. Cox Proportional Hazards Model for OS since the Start of Chemotherapy, Stratified by Hi
PD-L1 Expression All Patients *
PD-L1 negative
N/Deaths 51/48
Median OS (95% CI), months 7.5 (6.4-12.4)
PD-L1 weak positive
N/Deaths 99/91
Median OS (95% CI), months 9.8 (8.2-12.3)
Crude HR (95% CI) 1.04 (0.73-1.49)
Adjusted HR (95% CI) † 1.09 (0.76-1.58)
PD-L1 strong positive
N/Deaths 51/49
Median OS (95% CI), months 9.0 (6.4-11.1)
Crude HR (95% CI) 1.31 (0.88-1.97)
Adjusted HR (95% CI) † 1.36 (0.90-2.06)
PD-L1 strong or weak positive
N/Death 150/140
Median OS (95% CI), months 9.3 (7.8-11.0)
Crude HR (95% CI) 1.12 (0.80-1.57)
Adjusted HR (95% CI) † 1.17 (0.83-1.66)
NR, not reached.
* The date of the first dose of chemotherapy was missing for 3 patients; therefore, only 201 patients are inc
† HR: adjusting for age, sex, smoking status, histology, and performance status, with the PD-L1–negative gpatients with NSCLC, and several anti–PD-1 and PD-L1 antibodies
are currently under investigation [3–5]. Currently, the best predictive
biomarker for response to immunotherapy is protein expression of
PD-L1 in tumor samples measured by immunohistochemistry.
Several immunohistochemistry assays that use different antibodies
and various cutoff values are in current use. The role of PD-L1
expression as a prognostic biomarker in patients with advanced
NSCLC treated with chemotherapy remains unknown, and further
clinical studies are needed to evaluate the prognostic impact and
prevalence of PD-L1 expression in this group of patients.
We retrospectively assessed PD-L1 expression and its correlation
with clinicopathologic parameters and survival in a large cohort of
patients with advanced NSCLC who were offered first-line treatment
with standard platinum-doublet chemotherapy. PD-L1 expression,
measured by use of a prototype immunohistochemistry assay, could
be detected in 75% of the patients; 25% had strong staining intensitystologic Subtype
Adenocarcinoma Squamous Cell Carcinoma
30/29 9/7
10.7 (7.1-16.4) 19.9 (3.3-NR)
51/46 24/24
12.1 (8.5-15.0) 8.8 (6.1-12.2)
0.86 (0.54-1.36) 2.76 (1.09-7.03)
0.84 (0.53-1.34) 2.36 (0.84-6.63)
24/24 9/9
10.9 (6.9-13.3) 7.2 (0.9-10.2)
1.27 (0.74-2.19) 4.88 (1.56-15.14)
1.31 (0.76-2.27) 3.87 (1.05-14.26)
75/70 33/33
11.1 (9.2-13.3) 8.4 (6.6-9.8)
0.96 (0.62-1.48) 3.01 (1.21-7.51)
0.96 (0.62-1.48) 2.40 (0.87-6.60)
luded in survival analysis.
roup as the reference.
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using the same prototype immunohistochemistry assay and 22C3
antibody in Korean patients with predominately early-stage NSCLC
[27], we detected no significant statistical correlation between
clinicopathologic parameters and PD-L1 expression in our study. A
reasonable explanation for this discrepancy could be that 88% of the
patients had stage IV disease in our study. However, the prevalence of
PD-L1 strong positivity (25%) was similar in both studies. Studies of
surgically resected NSCLC tumors showed comparable expression
rates of PD-L1 [14,20,23]. PD-L1 expression was not statistically
associated with OS in our study.
In a study by Velcheti et al., the anti–PD-L1 5H1 antibody was
used in the immunohistochemistry assay. PD-L1 positivity was
defined as the automated quantitative analysis score of first signal
detection beyond the signal intensity in formalin-fixed, paraffin-em-
bedded samples from normal lung samples and negative controls.
Separate cohorts of patients with stage I to IV NSCLC treated at
hospitals in Greece or at Yale University were analyzed. Strong PD-L1
expression was detected in 25% (n = 75) of patients in the Greek
cohort and in 36% (n = 56) in the Yale cohort. However, the outcome
data differed from our results because positive PD-L1 expression was
associated with better clinical outcomes (HR = 0.61 for the Greek
cohort and HR = 0.63 for the Yale cohort) compared with negative
PD-L1 expression [22]. In our study, we focused on PD-L1
expression in patients with stage IIIb to IV NSCLC initially treated
with chemotherapy. In contrast, Velcheti et al. included all stages of
patients with NSCLC and provided no information concerning the
type of anticancer treatment. These differences in study design and
patient selection criteria could explain the discrepancy between the
reported survival results. A recently published study by D’Incecco
et al. evaluated PD-1 and PD-L1 immunohistochemical expression in
125 patients with advanced NSCLC [28]. Immunohistochemistry
was performed using the anti–PD-L1 ab58810 detection antibody,
and samples staining in N5% of tumor cells were considered to be
PD-L1 positive. Sixty-eight (55%) patients were classified as PD-L1
positive. This prevalence is similar to what we observed in our study,
where 75% of patients were either PD-L1 strong positive or PD-L1
weak positive. The lower cutoff limit used in our immunohistochem-
istry assay could explain the higher prevalence found in our study.
In concordance with our study, the authors of one meta-analysis
found no association between PD-L1 expression and survival (HR,
1.35; 95% CI, 0.81-2.23). However, two other recently published
meta-analyses found a high PD-L1 protein expression to be associated
with poor survival. The analyses also indicated that the study results
vary markedly primarily because of different immunohistochemistry
antibodies, evaluation methods for PD-L1 positivity (cutoff % or
H-score), and patient selection [24–26].
High PD-L1 expression on tumor cells indicates the presence of an
antitumor immune response. On the other hand, the role of this
antitumor immune response might not be such an important factor
for survival outcomes in patients treated with chemotherapy because
chemotherapy induces immunosuppression and suppresses the
antitumor immune response. Ongoing clinical trials are investigating
the efficacy of concomitant or sequential treatment with immuno-
therapy and conventional chemotherapy.
Different PD-L1 immunohistochemistry assays, using various
detection antibodies and cutoffs, are currently being developed and
evaluated clinically [29,30]. Because of timing and logistic
considerations, this study was conducted using a prototypeimmunohistochemistry assay. This prototype uses the same primary
antibody (22C3) and the same ancillary reagents as the clinical trial
assay used in clinical trials of pembrolizumab. However, the
prototype assay also uses a staining platform that is no longer
commercially available, and it employs a longer (overnight) antigen
retrieval step than the clinical trial assay. The prototype assay
produces a darker stain (likely due to the overnight antibody
incubation and possibly due to the double antigen retrieval), which
makes stained cells more noticeable but which also leads to higher
estimates of the percentage of cells stained. Fortunately, appropriately
adjusting the threshold for “strong positive” corrects for the higher
estimates of cell staining. The darker staining sometimes also obscures
cell morphology because of bleeding of the developer chromogen. In
addition to defining PD-L1 strong-positive and weak-positive using
prespecified criteria, we also performed sensitivity analyses for defining
PD-L1 strong and weak-positive using other criteria in this study (i.e.,
by quintile, quartile, or tertile of the proportional score) or treating the
IHC proportional score as a continuous variable. The results were
consistent in all of the sensitivity analyses (data not shown).
Limitations associated with the present study relate to its
retrospective design and its small sample size. On the other hand,
the patients included in our study were all treated at the same
institution and were uniformly followed with computed tomographic
scans at regular intervals both during and after treatment. The
completeness of all the clinical data leads to reliable survival analysis.
The eligibility criteria were broad and reflect the patient cohorts seen
in the everyday clinic given that, in Denmark, health care is almost
entirely public and free of charge and that all patients are diagnosed
and treated per established standards. The primary reason for
exclusion of patients was lack of sufficient remaining tumor tissue for
immunohistochemistry analysis.
The results of our study should pave the way for new prospective
studies of the predictive and prognostic role of PD-L1 expression
measured by immunohistochemistry in patients with NSCLC treated
with chemotherapy; such studies may bring interesting results,
especially concerning the efficacy of immunotherapy combined with
chemotherapy. The immune system is very dynamic, and future studies
should therefore optimally include repeat biopsies during treatment and
at progression or consecutive analysis of circulating biomarkers.
Conclusion
The prevalence of PD-L1 expression detected in the present study is
in concordance with previous studies. This indicates that a large
proportion of patients with advanced NSCLC have positive PD-L1
expression, which makes them potentially responsive to immuno-
therapy. There was no association between PD-L1 expression and
age, sex, smoking, or histology among these predominantly stage-IV
patients with NSCLC. Based on a prototype IHC assay and cutoff,
the results did not suggest that PD-L1 expression is a strong
prognostic marker among patients with advanced NSCLC treated
with chemotherapy.
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